Alnylam is the latest partner in the Medicines Manufacturing Innovation Centre’s third Grand Challenge project, which aims to revolutionise the manufacturing process for oligonucleotide therapies
Cardiovascular disease is the leading cause of death in the Asia Pacific, and it's a problem that will only intensify as populations continue to age
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
With the MONALEESA-2 final analysis, only Kisqali has reported statistically significant overall survival (OS) benefit with an aromatase inhibitor for postmenopausal women with HR+/HER2- advanced breast cancer in the first-line (1L) setting
Barbara Engelhardt moves her computational and statistics lab to Gladstone
The document is a global recommendation for circular packaging design. It will be updated and adapted to changes in the collection, sorting and recycling technology, as well as to future material development
Incorporating multi-modality image guidance, Ethos therapy provides the ability to personalize the patient's treatment based on their anatomy and position at the time of treatment
The institute will provide the world’s first unique and comprehensive capability to predict, prevent, respond and to recover from future pandemics
The medicine is now approved for eight indications across five different types of cancer in China.
Plasmacluster technology significantly inactivates SARS-CoV-2 contained in adherent saliva in an environment with 60% humidity where the physiological protective function is maintained
Subscribe To Our Newsletter & Stay Updated
